|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Esophageal Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Esophageal Diseases | |||||
| Esophageal Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Digestive System Diseases | |||||
| Digestive System Neoplasms | |||||
| Gastrointestinal Diseases | |||||
| Gastrointestinal Neoplasms | |||||
| Head and Neck Neoplasms | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| 4 | Interventions listed in this trial | ||||
| carboplatin | |||||
| fluorouracil | |||||
| paclitaxel | |||||
| conventional surgery | |||||
| radiation therapy | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antimetabolites | |||||
| Antimetabolites, Antineoplastic | |||||
| Antimitotic Agents | |||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Phytogenic | |||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Mitosis Modulators | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| Tubulin Modulators | |||||
| 6 | Sponsors listed in this trial | ||||
| Washington Hospital Center | |||||